Real-world use of dimehtyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus
Dimethyl fumarate (DMF) was recently approved by the European Medicines Agency for systemic treatment of moderate-to-severe chronic plaque psoriasis. Appropriate management of DMF treatment is required to achieve optimal clinical benefits. Seven dermatology experts gathered online for three meeting...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2022-12-01
|
| Series: | Dermatology Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/index.php/dr/article/view/9613 |
| _version_ | 1828084520235040768 |
|---|---|
| author | Martina Burlando Elena Campione Aldo Cuccia Giovanna Malara Luigi Naldi Francesca Prignano Leonardo Zichichi |
| author_facet | Martina Burlando Elena Campione Aldo Cuccia Giovanna Malara Luigi Naldi Francesca Prignano Leonardo Zichichi |
| author_sort | Martina Burlando |
| collection | DOAJ |
| description |
Dimethyl fumarate (DMF) was recently approved by the European Medicines Agency for systemic treatment of moderate-to-severe chronic plaque psoriasis. Appropriate management of DMF treatment is required to achieve optimal clinical benefits. Seven dermatology experts gathered online for three meetings to identify consensus on use of DMF in patient selection, drug dosage/titration, side effects management, and follow-up, with the aim to provide guidance on use of DMF for psoriasis in clinical dermatological practice based on literature data and expert opinion. Twenty statements were discussed and voted on using a facilitator-mediated modified Delphi methodology. Strong consensus was reached for all statements (agreement level of 100%). DMF treatment is characterized by dosage flexibility, sustained efficacy, high rates of drug survival, and low potential for drug–drug interactions. It can be used in a broad range of patients, including the elderly or those with comorbidities. Side effects (mainly gastrointestinal disorders, flushing, and lymphopenia) are frequently reported but are generally mild and transient and can be minimized by dosage adjustments and slow titration schedule. Hematologic monitoring throughout treatment course is required to reduce the risk of lymphopenia. This consensus document provides clinical dermatologists with answers on optimal use of DMF to treat psoriasis.
|
| first_indexed | 2024-04-11T04:26:14Z |
| format | Article |
| id | doaj.art-95fa095d8a104df59d172e3ec571b9e1 |
| institution | Directory Open Access Journal |
| issn | 2036-7392 2036-7406 |
| language | English |
| last_indexed | 2024-04-11T04:26:14Z |
| publishDate | 2022-12-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Dermatology Reports |
| spelling | doaj.art-95fa095d8a104df59d172e3ec571b9e12022-12-29T16:14:35ZengPAGEPress PublicationsDermatology Reports2036-73922036-74062022-12-0110.4081/dr.2023.9613Real-world use of dimehtyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensusMartina Burlando0Elena Campione1Aldo Cuccia2Giovanna Malara3Luigi Naldi4Francesca Prignano5Leonardo Zichichi6Dermatology Unit, IRCCS San Martino University Hospital, GenoaDermatology Unit, University of Rome ‘Tor Vergata’, RomeDermatology Unit, San Donato Hospital, ArezzoDermatology Unit, Metropolitan Hospital ‘Bianchi Melacrino Morelli’, Reggio CalabriaDermatology Unit, San Bortolo Hospital, VicenzaDermatology Unit, Department of Health Sciences, University of FlorenceDermatology Unit, Sant’Antonio Abate Hospital, Trapani Dimethyl fumarate (DMF) was recently approved by the European Medicines Agency for systemic treatment of moderate-to-severe chronic plaque psoriasis. Appropriate management of DMF treatment is required to achieve optimal clinical benefits. Seven dermatology experts gathered online for three meetings to identify consensus on use of DMF in patient selection, drug dosage/titration, side effects management, and follow-up, with the aim to provide guidance on use of DMF for psoriasis in clinical dermatological practice based on literature data and expert opinion. Twenty statements were discussed and voted on using a facilitator-mediated modified Delphi methodology. Strong consensus was reached for all statements (agreement level of 100%). DMF treatment is characterized by dosage flexibility, sustained efficacy, high rates of drug survival, and low potential for drug–drug interactions. It can be used in a broad range of patients, including the elderly or those with comorbidities. Side effects (mainly gastrointestinal disorders, flushing, and lymphopenia) are frequently reported but are generally mild and transient and can be minimized by dosage adjustments and slow titration schedule. Hematologic monitoring throughout treatment course is required to reduce the risk of lymphopenia. This consensus document provides clinical dermatologists with answers on optimal use of DMF to treat psoriasis. https://www.pagepress.org/journals/index.php/dr/article/view/9613psoriasis treatmentdimethyl fumaratelong-termconsensus |
| spellingShingle | Martina Burlando Elena Campione Aldo Cuccia Giovanna Malara Luigi Naldi Francesca Prignano Leonardo Zichichi Real-world use of dimehtyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus Dermatology Reports psoriasis treatment dimethyl fumarate long-term consensus |
| title | Real-world use of dimehtyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus |
| title_full | Real-world use of dimehtyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus |
| title_fullStr | Real-world use of dimehtyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus |
| title_full_unstemmed | Real-world use of dimehtyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus |
| title_short | Real-world use of dimehtyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus |
| title_sort | real world use of dimehtyl fumarate in patients with plaque psoriasis a delphi based expert consensus |
| topic | psoriasis treatment dimethyl fumarate long-term consensus |
| url | https://www.pagepress.org/journals/index.php/dr/article/view/9613 |
| work_keys_str_mv | AT martinaburlando realworlduseofdimehtylfumarateinpatientswithplaquepsoriasisadelphibasedexpertconsensus AT elenacampione realworlduseofdimehtylfumarateinpatientswithplaquepsoriasisadelphibasedexpertconsensus AT aldocuccia realworlduseofdimehtylfumarateinpatientswithplaquepsoriasisadelphibasedexpertconsensus AT giovannamalara realworlduseofdimehtylfumarateinpatientswithplaquepsoriasisadelphibasedexpertconsensus AT luiginaldi realworlduseofdimehtylfumarateinpatientswithplaquepsoriasisadelphibasedexpertconsensus AT francescaprignano realworlduseofdimehtylfumarateinpatientswithplaquepsoriasisadelphibasedexpertconsensus AT leonardozichichi realworlduseofdimehtylfumarateinpatientswithplaquepsoriasisadelphibasedexpertconsensus |